Tampere University Hospital
Tampere, Pirkanmaa, 33101, Finland
NCT Number: NCT06573671
The goal of this observational study is to describe a new disease condition of histiocytosis related to injecting drug use, its preconditions, symptoms, signs, findings, and prognosis in a detailed and systematic patient series in one referral center. The main question[s] it aims to answer are:
* to find specific histologic features in different tissues to help the differential diagnosis from other histiocytoses * to describe the value of chitotriosidase activity to screen this condition * to describe the value of various tissue biopsies in confirming the diagnosis * to describe the nature of polyvinylpyrrolidone accumulation in tissue macrophages by novel special microscopic techniques * to find new tandem mass spectrometry methodology to prove polyvinylpyrrolidone accumulation in macrophages * to show that polyvinylpyrrolidone treatment activates macrophages to histiocytes and causes povidone accumulation within the cells in in vitro experiments * to evaluate the pathology of macrophage activation to histiocytes by transcriptomics
The patient history will be collected from the data produced by follow-up of cases followed up in a single center. A subgroup of participants will be given an opportunity to sign informed consent to give access to/donate blood and tissue samples to search for techniques to prove polyvinylpyrrolidone storage within histiocytes, and to search for transcriptomics signal(s) in histiocytes.
Researchers will compare blood and tissue samples from the biobank as controls.
Interested in participating?
Request Info18 year–70 year
All sexes
Observational
Tampere, Pirkanmaa, 33101, Finland
Comprehensive patient data (disease history, findings, complications, laboratory findings, histopathology, and imaging) will be obtained from patient records of a single university hospital. Coded histiocytosis-positive tissue samples will be compared to biobank samples from corresponding tissues from healthy and other histiocytosis tissue samples to show polyvinylpyrrolidone storage with novel methodologies.
In addition, if a study participant who is followed up clinically, signs informed consent, monocytes are separated from a blood sample, differentiated to macrophages, and exposed to polyvinylpyrrolidone. Various novel methods will be utilized to explore polyvinylpyrrolidone within histiocytes.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The amount of patients with increased chitotriosidase, and the extent of elevation of chitotriosidase
to show polyvinylpyrrolidone presence in histiocytes of injecting drug users compared to controls
to show polyvinylpyrrolidone presence in histiocytes of injecting drug users compared to controls
to show polyvinylpyrrolidone presence in histiocytes of injecting drug users compared to controls
To describe pathologic signals of polyvinylpyrrolidone-exposed in vitro histiocytes of injecting drug users compared to control samples
Time frame: 10 years
To describe phenotype
Time frame: 10 years
Is chitotriosidase activity associated with polyvinylpyrrolidone histiocytosis
Time frame: 10 years
Mortality
Time frame: 10 years
Search for specific polyvinylpyrrolidone fluorescence signal
Time frame: 10 years
search for specific polyvinylpyrrolidone signal within cells
Time frame: 10 years
search for specific polyvinylpyrrolidone signal within cells
Time frame: 10 years
Search for immunologic pathway-specific abnormalities to guide treatment in cases compared with controls
Tampere University Hospital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05786924
Acquired Resistance to KRAS G12C Inhibitor, BRAF
Gilbert, Arizona, United States
View Trial DetailsNCT05915208
Erdheim-Chester Disease, Hemic and Lymphatic Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT03127709
Hemic and Lymphatic Diseases, Histiocytosis
Basking Ridge, New Jersey, United States
View Trial DetailsNCT04943198
Hemic and Lymphatic Diseases, Histiocytosis
Warsaw, Mazovian, Poland
View Trial Details